- Record: found
- Abstract: found
- Article: not found
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Paul A Meyers
1 ,
Cindy L Schwartz ,
Mark Krailo ,
Eugenie S Kleinerman ,
Donna Betcher ,
Mark L Bernstein ,
Ernest Conrad ,
William Ferguson ,
Mark Gebhardt ,
Allen M Goorin ,
Michael B Harris ,
John Healey ,
Andrew Huvos ,
Michael Link ,
Joseph Montebello ,
Helen Nadel ,
Michael Nieder ,
Judith Sato ,
Gene Siegal ,
Michael Weiner ,
Robert Wells ,
Lester Wold ,
Richard Womer ,
Holcombe Grier
Mar 20 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS).